Syngene International acquires its first US manufacturing facility for USD 50 million, expanding its reach in human and animal health markets.

Biocon arm Syngene International announced today the acquisition of its first biologics facility in the USA from Emergent ...

The facility, which the contract research firm said is strategically located near key biotech hubs in the Northeast U.S., is ...

Syngene International acquires US manufacturing facility, expanding bioreactor capacity and global service capabilities for pharmaceutical innovation.

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...